托珠单抗及其在皮肤病中的应用。

IF 2 Q3 Medicine

Giornale Italiano Di Dermatologia E Venereologia Pub Date : 2020-12-01 DOI:10.23736/S0392-0488.20.06772-3

L. Mastorino, G. Avallone, P. Dapavo, M. Merli, A. Agostini, D. Grandinetti, M. Fierro, P. Quaglino, S. Ribero

{"title":"托珠单抗及其在皮肤病中的应用。","authors":"L. Mastorino, G. Avallone, P. Dapavo, M. Merli, A. Agostini, D. Grandinetti, M. Fierro, P. Quaglino, S. Ribero","doi":"10.23736/S0392-0488.20.06772-3","DOIUrl":null,"url":null,"abstract":"The monoclonal anti-IL6 receptor antibody called Tocilizumab is widely used by rheumatologists for joint diseases. Its application in dermatology has mainly concerned scleroderma and Systemic Sclerosis in the last years. The most varied skin diseases treated with Tocilizumab, such as Psoriasis, Psoriatic Arthritis, Behcet's Disease, Lupus, and the already mentioned Scleroderma up to multi-organ syndromes with skin involvement will be discussed. At the same time, there have been several side reactions to the drug involving the skin forcing careful skin monitoring during treatment. Despite the evidence currently available in the appropriate literature, there is no formal recommendation for any of these diseases to use Tocilizumab for therapeutic purposes. This review aims to collect all the main evidence on the use and involvement of the drug in dermatological practice in order to stimulate further research or hypothesize on possible therapeutic options.","PeriodicalId":49071,"journal":{"name":"Giornale Italiano Di Dermatologia E Venereologia","volume":"15 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tocilizumab and its usage for skin diseases.\",\"authors\":\"L. Mastorino, G. Avallone, P. Dapavo, M. Merli, A. Agostini, D. Grandinetti, M. Fierro, P. Quaglino, S. Ribero\",\"doi\":\"10.23736/S0392-0488.20.06772-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The monoclonal anti-IL6 receptor antibody called Tocilizumab is widely used by rheumatologists for joint diseases. Its application in dermatology has mainly concerned scleroderma and Systemic Sclerosis in the last years. The most varied skin diseases treated with Tocilizumab, such as Psoriasis, Psoriatic Arthritis, Behcet's Disease, Lupus, and the already mentioned Scleroderma up to multi-organ syndromes with skin involvement will be discussed. At the same time, there have been several side reactions to the drug involving the skin forcing careful skin monitoring during treatment. Despite the evidence currently available in the appropriate literature, there is no formal recommendation for any of these diseases to use Tocilizumab for therapeutic purposes. This review aims to collect all the main evidence on the use and involvement of the drug in dermatological practice in order to stimulate further research or hypothesize on possible therapeutic options.\",\"PeriodicalId\":49071,\"journal\":{\"name\":\"Giornale Italiano Di Dermatologia E Venereologia\",\"volume\":\"15 1\",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2020-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Giornale Italiano Di Dermatologia E Venereologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.23736/S0392-0488.20.06772-3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale Italiano Di Dermatologia E Venereologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S0392-0488.20.06772-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

单克隆抗il6受体抗体Tocilizumab被风湿病学家广泛用于关节疾病。近年来，其在皮肤病学中的应用主要涉及硬皮病和系统性硬化症。将讨论Tocilizumab治疗的各种皮肤病，如银屑病、银屑病关节炎、白塞病、狼疮和已经提到的硬皮病，直至皮肤受累的多器官综合征。同时，在治疗过程中，该药物有几种涉及皮肤的副作用，需要仔细监测皮肤。尽管目前在适当的文献中有证据，但没有正式推荐将Tocilizumab用于任何这些疾病的治疗目的。本综述旨在收集有关该药物在皮肤病学实践中的使用和参与的所有主要证据，以刺激进一步的研究或对可能的治疗选择提出假设。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Tocilizumab and its usage for skin diseases.

The monoclonal anti-IL6 receptor antibody called Tocilizumab is widely used by rheumatologists for joint diseases. Its application in dermatology has mainly concerned scleroderma and Systemic Sclerosis in the last years. The most varied skin diseases treated with Tocilizumab, such as Psoriasis, Psoriatic Arthritis, Behcet's Disease, Lupus, and the already mentioned Scleroderma up to multi-organ syndromes with skin involvement will be discussed. At the same time, there have been several side reactions to the drug involving the skin forcing careful skin monitoring during treatment. Despite the evidence currently available in the appropriate literature, there is no formal recommendation for any of these diseases to use Tocilizumab for therapeutic purposes. This review aims to collect all the main evidence on the use and involvement of the drug in dermatological practice in order to stimulate further research or hypothesize on possible therapeutic options.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Giornale Italiano Di Dermatologia E Venereologia DERMATOLOGY-

CiteScore

1.90

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The journal Giornale Italiano di Dermatologia e Venereologia publishes scientific papers on dermatology and sexually transmitted diseases. Manuscripts may be submitted in the form of editorials, original articles, review articles, case reports, therapeutical notes, special articles and letters to the Editor. Manuscripts are expected to comply with the instructions to authors which conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Editors by the International Committee of Medical Journal Editors (www.icmje.org). Articles not conforming to international standards will not be considered for acceptance.